Alembic Pharmaceuticals has agreed to invest $1.0 million in the form of promissory notes issued by RIGImmune, Inc., a start-up entity in the research and experimental development of new chemical entities. The investment will help Alembic Pharmaceuticals enter a niche segment of new chemical entities.